11 – 20 of 86
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Antioxidants reduce muscular dystrophy in the dy2J/dy2J mouse model of laminin α2 chain-deficient muscular dystrophy
(
- Contribution to journal › Article
- 2019
-
Mark
A mutation-independent approach for muscular dystrophy via upregulation of a modifier gene
(
- Contribution to journal › Letter
-
Mark
Effects of N-acetyl-L-cysteine and vitamin E on congenital muscular dystrophy type 1A disease progression in mice
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
- 2018
-
Mark
Potential therapies and biomarkers for LAMA2-CMD. Does the microRNA hype deliver?
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Laminin α1 reduces muscular dystrophy in dy2Jmice
(
- Contribution to journal › Article
-
Mark
Effects of metformin on congenital muscular dystrophy type 1A disease progression in mice: a gender impact study
2018) In Scientific Reports(
- Contribution to journal › Article
-
Mark
Exploratory Profiling of Urine MicroRNAs in the dy2J/dy2J Mouse Model of LAMA2-CMD : Relation to Disease Progression
(
- Contribution to journal › Article
- 2017
-
Mark
Potent pro-inflammatory and profibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin α2 chaindeficient muscular dystrophy
(
- Contribution to journal › Article
-
Mark
Bioenergetic Impairment in Congenital Muscular Dystrophy Type 1A and Leigh Syndrome Muscle Cells
(
- Contribution to journal › Article
-
Mark
Absence of microRNA-21 does not reduce muscular dystrophy in mouse models of LAMA2-CMD
(
- Contribution to journal › Article